As a marker of poor prognosis and a potential therapeutic target of AML, a similar mechanism may be helpful for inhibiting ALL development, and the decreased level of SPARC may account for a better prognosis of CNSL, since the levels of SPARC significantly declined in subjects when they CR was achieved in our study. This evidence concerns the gene SPARC and acute lymphoblastic leukemia.